daytime therapy for mild obstructive sleep apnea
Begin your journey towards better sleep with the eXciteOSA®! eXciteOSA® therapy is the only FDA authorized, clinically proven daytime therapy for mild obstructive sleep apnea (OSA) and snoring. eXciteOSA® targets the root cause of mild OSA and snoring – the loss of muscle tone of the tongue – rather than simply relieving the symptoms.
OSA is often caused by collapsed tissue in the airway. eXciteOSA® prevents the airway from collapsing by improving the muscle function of the tongue through stimulation therapy. Improvement of muscle function not only prevents the upper airway tissue from collapsing but ensures that the upper airway remains open during sleep, thereby improving sleep quality.
EXCITEOSA® IS CONVENIENT AND SIMPLE TO USE:
- The mouthpiece gets positioned onto your tongue.
- The app activates and customizes each therapy session, making this experience unique to you.
- The app tracks your progress and keeps you focused on therapy goals.
View the eXciteOSA® Quick Start Guide by clicking the button below.
How eXciteOSA® Works:
eXciteOSA® is the only daytime solution clinically proven to significantly reduce mild obstructive sleep apnea and snoring.1,2,3
Each 20-minute session includes four 5-minute phases, each designed to train your tongue muscle in a different way.
Here’s the timeline for treatment:
- First six weeks: one 20-minute session a day
- After six weeks: two 20-minute sessions per week
Want to learn more?
This prescription product was just approved by the FDA. If you are interested or would like more information about pre-ordering the eXciteOSA®, you can contact us via chat, email, or over the phone.
Prefer to have us contact you?
Please fill out the form below.
E.Wessoleck et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22(Suppl 2): 47–52.
A.Sama et al. Daytime Intraoral Neurostimulation with Snoozeal® for treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes, 2018.
eXciteOSA® White Paper (2020). Clinical study of 115 patients with snoring or mild OSA (Apnea-Hypopnea Index (AHI) <15 n=65) completed the trial. Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPAT® night sleep studies before and after the use of the device. An intra-oral tongue stimulator device was used for 20 mins, once a day for 6-week period. (Internal publication by SMT for educational purposes and submission.)